NICE backs Daiichi's anticoagulant Lixiana, Takeda's Crohn's med Entyvio; Sucampo offers $278M for Japanese supply partner;

@FiercePharma: UPDATED: With vote approaching, Perrigo chief slams Mylan's 'troubling' values. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Shire rejigs manufacturing deal to step up Cinryze production. Story | Follow @CarlyHFierce

> Cost-effectiveness watchdogs in the U.K. backed Daiichi Sankyo's new anticoagulant Lixiana (edoxaban), a latecomer to the warfarin-alternative field, to treat and prevent deep vein thrombosis and pulmonary embolism. Report

> The National Institute for Health and Care Excellence (NICE) also backed Takeda's Crohn's disease drug Entyvio (vedolizumab). Report

> Maryland-based Sucampo launched a tender offer to buy the Japan's R-Tech Ueno, which manufactures Sucampo's Amitiza gastrointestinal drug, for about $278 million. Release

> India's Aurobindo Pharma brought on a former Ranbaxy Laboratories executive, Sanjeev Dani, to serve as its chief operating officer. Report

> Brazil's pharma market will near $48 billion by 2020, GlobalData says. Release

> Amneal has created a new biosciences unit that will focus on injectables, oncologics, biosimilars and other products that have high barriers to entry. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Startup wins $9.4M Series A to back speedy handheld vital sign scanner. Article | Follow @FierceMedDev

@VarunSaxena2: Medtronic to buy Twelve for $408M+, joining Abbott and Edwards on the transcatheter mitral valve bandwagon. Report | Follow @VarunSaxena2

@EmilyWFierce: Readers weighed in on who $AGN should buy next. Find out who emerged the winner. More from FiercePharma | Follow @EmilyWFierce

> GE lends radiology tech to Philadelphia hospital in contract deal. More

> Noninvasive, point-of-care kidney monitor startup raises $22.4M to get to market. Story

> AirXpanders' tissue expander for breast reconstruction meets primary endpoint. Article

Biotech News

@FierceBiotech: TSRI researchers spotlight a hidden cause of antibiotics resistance. Story from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: Immatics, MD Anderson partner on a $60M immuno-oncology T-cell spinout. News | Follow @JohnCFierce

> Pharma giants line up behind an $83M crossover round for IPO-bound Merus. News

> Sarepta snags priority review status to keep pace with BioMarin in DMD race. Article

> Jeb Bush's unfulfilled promise shows the perils of building blockbuster biotech clusters. Story

Biotech Research News

> New method uses coated gold nanorods to treat pain. Item

> UCSF cardiology chief builds a case for two new targets for heart drugs. More

> UC Berkeley team says brown fat implants may effectively tackle obesity. Report

> TSRI researchers spotlight a hidden cause of antibiotics resistance. Article

> MSK: 'This is what the future of precision medicine looks like.' Story

Diagnostics News

> Sequenom strikes liquid biopsy research deal with UC San Diego Moores. Item

> Roche shops around for sequencing tech with Lumora buy. More

> Illumina makes moves in China with Burning Rock cancer Dx deal. Report

> Roche's M&A party rages on with Kapa Biosystems deal. Story

> Guardant Health teams with Flatiron for liquid biopsy-based drug development platform. Article

Pharma Marketing News

> Novo pulls blockbuster diabetes med Victoza off the Type 1 track. Report

> Eli Lilly slaps down Teva's challenge to Alimta exclusivity. Item

> AstraZeneca uses snails and overstuffed luggage to push OIC awareness--and its branded solution. Article

> Boehringer Ingelheim partners with telenovela for diabetes storyline. News

> Can Sprout's Addyi shrug off serious side effects? These blockbusters did. Story

And Finally... The FDA cracked down on Just Mayo's maker because the product lacks ingredients that make it an official mayonnaise. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.